Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyo Jin | - |
dc.contributor.author | Kim, Hyunsuk | - |
dc.contributor.author | Shin, Nara | - |
dc.contributor.author | Na, Ki Young | - |
dc.contributor.author | Kim, Yong Lim | - |
dc.contributor.author | Kim, Daejung | - |
dc.contributor.author | Chang, Jae Hyun | - |
dc.contributor.author | Song, Young Rim | - |
dc.contributor.author | Hwang, Young-Hwan | - |
dc.contributor.author | Kim, Yon Su | - |
dc.contributor.author | Ahn, Curie | - |
dc.contributor.author | Lee, Joongyub | - |
dc.contributor.author | Oh, Kook-Hwan | - |
dc.date.available | 2020-02-28T23:46:18Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-05-25 | - |
dc.identifier.issn | 1471-2369 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14531 | - |
dc.description.abstract | Background: Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in dialyzed patients. Objectives: The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients. Additionally, we analyzed change in FGF23 levels between two treatments to explore the cinacalcet effect in lowering FGF23. Design: Multicenter, open-labeled, randomized controlled study. Setting: Seven university-affiliated hospitals in Korea. Participants: Overall, 66 peritoneal dialysis patients were enrolled. Intervention: Sixty six patients were randomly assigned to treatment with either cinacalcet + oral vitamin D (cinacalcet group, n = 33) or oral vitamin D alone (control group, n = 33) to achieve K/DOQI targets. CUPID included a 4-week screening for vitamin D washout, a 12-week dose-titration, and a 4-week assessment phases. We calculated mean values of iPTH, Ca, P, Ca x P, during assessment phase and final FGF23 to assess the outcome. Main outcome measures: Achievement of >30% reduction of iPTH from baseline (primary) and FGF23 reduction (secondary). Results: 72.7% (n = 24) of the cinacalcet group and 93.9% ( n = 31) of the control group completed the study. Cinacalcet group received 30.2 +/- 18.0 mg/day of cinacalcet and 0.13 +/- 0.32 mu g/d oral vitamin D (P < 0.001 vs. control with 0.27 +/- 0.18 mu g/d vitamin D). The proportion of patients who reached the primary endpoint was not statistically different (48.5% vs. 51.5%, cinacalcet vs. control, P = 1.000). After treatment, cinacalcet group experienced a significant reduction in FGF23 levels (median value from 3,960 to 2,325 RU/ml, P = 0.002), while an insignificant change was shown for control group (from 2,085 to 2,415 RU/ml). The percent change of FGF23 after treatment was also significantly different between the two groups (- 42.54% vs. 15.83%, P = 0.008). After adjustment, cinacalcet treatment was independently associated with the serum FGF23 reduction. Conclusion: Cinacalcet treatment was independently associated with the reduction of FGF23 in our PD patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.relation.isPartOf | BMC NEPHROLOGY | - |
dc.subject | CHRONIC KIDNEY-DISEASE | - |
dc.subject | LEFT-VENTRICULAR HYPERTROPHY | - |
dc.subject | SECONDARY HYPERPARATHYROIDISM | - |
dc.subject | HEMODIALYSIS-PATIENTS | - |
dc.subject | FGF23 LEVELS | - |
dc.subject | PHOSPHATE | - |
dc.subject | FIBROBLAST-GROWTH-FACTOR-23 | - |
dc.subject | FGF-23 | - |
dc.subject | PHOSPHORUS | - |
dc.subject | METABOLISM | - |
dc.title | Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000319810600001 | - |
dc.identifier.doi | 10.1186/1471-2369-14-112 | - |
dc.identifier.bibliographicCitation | BMC NEPHROLOGY, v.14 | - |
dc.identifier.scopusid | 2-s2.0-84878004438 | - |
dc.citation.title | BMC NEPHROLOGY | - |
dc.citation.volume | 14 | - |
dc.contributor.affiliatedAuthor | Chang, Jae Hyun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Cinacalcet | - |
dc.subject.keywordAuthor | Fibroblast growth factor 23 | - |
dc.subject.keywordAuthor | Peritoneal dialysis | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | LEFT-VENTRICULAR HYPERTROPHY | - |
dc.subject.keywordPlus | SECONDARY HYPERPARATHYROIDISM | - |
dc.subject.keywordPlus | HEMODIALYSIS-PATIENTS | - |
dc.subject.keywordPlus | FGF23 LEVELS | - |
dc.subject.keywordPlus | PHOSPHATE | - |
dc.subject.keywordPlus | FIBROBLAST-GROWTH-FACTOR-23 | - |
dc.subject.keywordPlus | FGF-23 | - |
dc.subject.keywordPlus | PHOSPHORUS | - |
dc.subject.keywordPlus | METABOLISM | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.